AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06071871
Drug: Glofitamab
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8. Patients need to stay in hospital for 24 hours.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15. (Patients may need to stay in hospital for 24 hours.) Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-12 (as relevant).
Trial: NCT05319093
Drug: Ozanimod
RxNorm normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Three-months, longitudinal observational period
Trial: NCT06071871
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab is given intravenously at a dose of 1.8mg/kg on Cycle 1 Day 2, and then Day 1 of Cycle 2-Cycle 6.
Trial: NCT06071871
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
Trial: NCT05692180
Drug: Benralizumab
RxNorm normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Benralizumab active solution will be administered SC to the patients.
Trial: NCT06335147
Drug: Serplulimab, mFOLFOX6
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab，200mg，iv，q2w，d1； mFOLFOX6（Oxaliplatin: 85 mg/m2，LV ：400mg/m2，Fluorouracil： 400mg/m2 d1，2400 mg/m2 continuous intravenous drip for 46-48 hours；q2w）
Trial: NCT06045247
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT06045247
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT06045247
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT06045247
Drug: Epcoritamab
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given under the skin
Trial: NCT06453083
Drug: Medrol
RxNorm normalized name: Medrol
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medrol tablets will be dispensed to the participants for 6-days.
Trial: NCT06315959
Drug: morphine PCA
RxNorm normalized name: lauryl PCA
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
Trial: NCT06315959
Drug: morphine PCA
RxNorm normalized name: lauryl PCA
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: V PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
Trial: NCT06330077
Drug: Ifenprodil
RxNorm normalized name: ifenprodil
DrugBank: Ifenprodil (DB08954)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment administration
Trial: NCT05080842
Drug: AC682
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive AC682 by mouth daily in 28-day cycles.
Trial: NCT04701476
Drug: TATE and pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.
Trial: NCT04701476
Drug: TAS-102 pill
RxNorm normalized name: Ta
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.
Trial: NCT04701476
Drug: Regorafenib Pill
RxNorm normalized name: regorafenib Pill
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.
Trial: NCT03828201
Drug: Delamanid
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Frequency: daily Route of administration: oral~Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.
Trial: NCT03828201
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequency: daily Route of administration: oral~Levofloxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis.
Trial: NCT03828201
Drug: Bedaquiline
RxNorm normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Frequency: daily Route of administration: oral~Bedaquiline is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.
Trial: NCT03828201
Drug: Clofazimine
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequency: daily Route of administration: oral~Clofazimine has shown activity against multidrug-resistant tuberculosis (MDR-TB) and is now recommended by the World Health Organization (WHO) to treat drug resistant tuberculosis as a Group B drug. It is thought that clofazimine acts by inhibiting the formation of matrixes within the DNA and thus delaying the growth of the bacterium. Clofazimine first received FDA approval in 1986, although its use in the treatment of MDR-TB has not been approved by any stringent regulatory authorities and it is therefore used off-label for this function.
Trial: NCT03828201
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequency: daily Route of administration: oral~Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics.
Trial: NCT04831684
Drug: GET73
RxNorm normalized name: Glatiramer acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be getting GET73 for 8 days of dosing.
Trial: NCT05586763
Drug: Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient with vertigo symptoms will be registered in vertigo list after written consent taken. The ED doctor will take one paper from the vertigo list box and will write the case there including patient ID, date, age and symptoms. Assessment (VAS \& EEV) will be done in the pre- medication 0 min, and at 60 mins posts anti-vertigo medication. The medication will be provided blindly through the pharmacy. Any possible medication side effect and any possible further work up done for patient will be involved in each paper as ED doctor will put a tick near each point. Score will be written in papers as per patient evaluation of their symptoms grade from 1-10. The need for rescue medication ( betahisten or ondansetron ) will be recorded in the paper or is need eply manuver. Principle investigator in each centre will be responsible to collect the papers for analysis by end of each weeks.
Trial: NCT06295328
Drug: Terbinafine
RxNorm normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: terbinafine 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
Trial: NCT06295328
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir 245mg standard of care
Trial: NCT04764656
Drug: Brolucizumab
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
Trial: NCT04726098
Drug: Dexamethasone high dose
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High doses: dexamethasone 20 mg/day 5 days + 10 mg/day 5 days (total 10 days)
Trial: NCT04726098
Drug: Dexamethasone low dose
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses: dexamethasone 6 mg/day 10 days.
Trial: NCT03569514
Drug: AIGIV
RxNorm normalized name: IGIV
DrugBank: Inarigivir (DB15062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthrax Immune Globulin Intravenous (Human)
Trial: NCT05082584
Drug: Vadadustat
RxNorm normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vadadustat tablet orally once a day for 52 weeks
Trial: NCT05280483
Drug: ABSK021 with fed state
DrugBank: BSK02 (DB17434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg ABSK021 (1x25 mg ABSK021 capsule) with food
Trial: NCT04751929
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Taken orally 2x daily
Trial: NCT04751929
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenously Day 1 of 21 day cycle
Trial: NCT05280483
Drug: ABSK021 with fasted state
DrugBank: BSK02 (DB17434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg ABSK021 (1x25 mg ABSK021 capsule) without food
Trial: NCT05736952
Drug: Oral Topotecan Combined With Anlotinib
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan hydrochloride capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is, 21 days (3 weeks) as a course of treatment, a total of 6 courses of administration.；Anlotinib hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for 14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a course of treatment.
Trial: NCT00000737
Drug: Dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000737
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04946227
Drug: Pembrolizumab 200mg +Paclitaxel 80mg/m2
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200mg +Paclitaxel 80mg/m2
Trial: NCT05659537
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered SC
Trial: NCT05489237
Drug: IDRX-42
RxNorm normalized name: IDRX-42
DrugBank: IDRX-42 (DB18087)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.
Trial: NCT05868213
Drug: Cannabis (smoked flower)
RxNorm normalized name: CANNABIS SATIVA FLOWERING TOP
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Directed Use (ad-libitum)
Trial: NCT05214417
Drug: Ketamine Injectable Solution
RxNorm normalized name: ketamine Injectable Solution
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 IM ketamine sessions with psychotherapy, spaced 9-15 days apart
Trial: NCT05160727
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg ivgtt d1 q3w
Trial: NCT05160727
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concurrent Chemoradiotherapy:~Irinotecan: 80mg/m2/w (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2/w (UGT1A1\*28 and \*6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1\*28 and \*6: 7/7+GG or 6/6+AA or 6/7+GA) Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w.
Trial: NCT05218499
Drug: Brigimadlin (BI 907828)
RxNorm normalized name: Brigimadlin
DrugBank: Brigimadlin (DB18578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigimadlin (BI 907828)
Trial: NCT05999084
Drug: Anti-amyloid Monoclonal Antibodies (mAbs)
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Amyl acetate (DB15927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions of lecanemab occur every 2-weeks as indicated in the FDA labeling. After 18 months of treatment, an amyloid positron emission tomography (PET) scan with FDA-approved radiotracer is performed to confirm clearance of amyloid pathology. It is anticipated that most individuals treated with lecanemab for 18 months will no longer have positive amyloid PET scans. In those instances where persistent amyloid pathology is seen, every 2-week treatment with lecanemab will be continued for an additional 6 months with repeat amyloid PET scan until amyloid clearance is achieved. If an individual has progressed to moderate or severe stages of AD dementia during the initial 18 months of treatment and amyloid PET shows failure to clear amyloid pathology, treatment will be terminated. Dosing frequency after 18 months (or after amyloid clearance) remains unclear and will need to be determined with additional evidence development.
Trial: NCT05058755
Drug: tislelizumab, azacytidine, lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tislelizumab, 200mg, iv, day 1, every 21 days.~azacytidine, 75mg/m2, ih, days 1-7, every 21 days.~lenalidomide, 25mg, po, days 1-14, every 21 days.
Trial: NCT06433609
Drug: SHR-A1811
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Via intravenous infusion
Trial: NCT06433609
Drug: SHR-A1921
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Via intravenous infusion
Trial: NCT06433609
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Via intravenous infusion
Trial: NCT05718882
Drug: Lenvatinib Oral Product Plus VIC1911
RxNorm normalized name: lenvatinib Oral Product
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib: 8mg/day (≤ 60Kg), oral. VIC-1911:Groups were divided: 100mg bid（DL1, dose level 1）; 150mg bid（DL2）; 200mg bid(DL3), oral. 50mg bid is defined as DL(-1), 250mg bid is defined as DL(+1). A Bayesian Optimal Interval design schema will be followed to establish the maximum tolerated dose (MTD) of lenvatinib plus VIC-1911 combination and RP2D of VIC-1911 in HCC patients. The study would follow the Bayesian Optimal Interval Design with level size of 2 patients. The R package BOIN is available from CRAN.
Trial: NCT02968641
Drug: Lonafarnib
RxNorm normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antiviral farnesyltransferase inhibitor
Trial: NCT02968641
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CYP 3A4 inhibitor, lonafarnib booster
Trial: NCT05860374
Drug: Recombinant oncolytic herpes simplex virus type 1 (R130)
RxNorm normalized name: Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Trial: NCT06552429
Drug: Peginterferon α-2b injection
RxNorm normalized name: peginterferon alfa-2b Injection
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon α-2b injection, 135 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
Trial: NCT06552429
Drug: Peginterferon α-2b injection
RxNorm normalized name: peginterferon alfa-2b Injection
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon α-2b injection, 180 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
Trial: NCT05441501
Drug: JNJ-80038114
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-80038114 will be administered.
Trial: NCT04016818
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant will be injected IV (intravenously) with 10 ± 2 mCi of 18F-FDG.
Trial: NCT03386071
Drug: Trametinib 2 mg
RxNorm normalized name: trametinib 2 MG
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dosage of trametinib for oral administration is 2mg once daily.
Trial: NCT06073184
Drug: Mounjaro
RxNorm normalized name: Mounjaro
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tirzepatide injection, starting dose is 2.5mg injected subcutaneously once weekly. After 4 weeks, dose should be increased to 5mg once weekly. The dose then can be increased in 2.5mg increments after no less than 4 weeks on current dose to maximum dose of 15mg once weekly.
Trial: NCT06073184
Drug: Mirena
RxNorm normalized name: Mirena
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel-releasing Intrauterine System (52mg) to deliver up to 20 mcg levonorgestrel per day
Trial: NCT05341076
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oxytocin augmentation: given with further delay of labor (according to the point of intervention of the partograph or the scale)
Trial: NCT06096038
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine 30 mg/meter square IV × 3 days
Trial: NCT04491942
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04491942
Drug: Elimusertib
RxNorm normalized name: Elimusertib
DrugBank: Elimusertib (DB19041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04491942
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05071807
Drug: Pecans
RxNorm normalized name: Pecans
DrugBank: Pecan (DB10555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 oz of pecans daily to replace a typical snack and continue consuming their usual diet for 12 weeks.
Trial: NCT05595642
Drug: Astegolimab
RxNorm normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC astegolimab Q2W or Q4W
Trial: NCT03954327
Drug: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
Trial: NCT03954327
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir (RTF) 600 mg two tablets by mouth once per day
Trial: NCT05467943
Drug: Tazemetostat
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle
Trial: NCT06350318
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib is an anti-cancer medication administered orally.
Trial: NCT06350318
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab is a biologic medication administered intravenously or subcutaneously.
Trial: NCT05434689
Drug: Iberdomide
RxNorm normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.
Trial: NCT05434689
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma
Trial: NCT05434689
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Corticosteroid active against multiple myeloma in combination with other agents
Trial: NCT05434689
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Second generation proteasome inhibitor with activity in multiple myeloma
Trial: NCT05795517
Drug: HSK31679 low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HSK31679 low dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
Trial: NCT00997542
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no